NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

LOS ANGELES, CA / ACCESS Newswire / February 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc ("GSK" or "the Company") (NYSE: GSK) for violations of §§10 (b) and 20 ...

A new method has been created for determining N-nitrosamines (NAs) in pharmaceutical preparations using liquid chromatography ...

Librela (bedinvetmab injection) is a monthly injectable monoclonal antibody, for which real-world drug experience data has ...

This article is authored by Ranjit Barshikar, CEO, QbD International, CGMP Consulting, United Nations Adviser.